News &amp; Updates

A history of vascular disease appears to contribute to worse long-term outcomes in patients with atrial fibrillation (AF), but treatment with oral anticoagulation (OAC) helps, suggests a recent study.

NOACs help improve outcomes in AF with vascular disease

Novel therapies tied to drop in colectomy rate in paediatric UC

The risk of colectomy in paediatric onset ulcerative colitis (UC) has significantly decreased at the population level along with an increase in the use of immunosuppressants and antitumour necrosis factor (anti-TNF), reports a study.

Novel therapies tied to drop in colectomy rate in paediatric UC

Remibrutinib improves CSU symptoms in phase III trials

Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.

Remibrutinib improves CSU symptoms in phase III trials

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

Treatment with fezolinetant 45 mg outperforms other nonhormone therapies (non-HTs) in terms of minimizing the frequency of moderate-to-severe vasomotor symptoms (VMS) in women undergoing menopause, according to a study from the US.

Fezolinetant superior to other non-HTs at reducing bothersome VMS due to menopause

Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial

Four-day-a-week dosing of dual therapy for HIV performs similarly to daily doses in terms of sustaining viral suppression in the DUETTO trial. However, virological failure (VF) and drug resistance rates were higher with the 4-day/week dosing regimen.

Intermittent dosing of dual HIV therapy for HIV disappoints in DUETTO trial

Empagliflozin of little benefit in patients hospitalized for COVID-19

In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.

Empagliflozin of little benefit in patients hospitalized for COVID-19

04 Dec 2023

Pertuzumab plus high-dose trastuzumab shows promise for selected patients with HER2-positive MBC

Treatment with pertuzumab plus high-dose trastuzumab appears to confer survival benefits in patients with HER2-positive metastatic breast cancer (MBC) with progressive central nervous system (CNS) metastases following radiotherapy, according to the phase II PATRICIA study.

Pertuzumab plus high-dose trastuzumab shows promise for selected patients with HER2-positive MBC

Ciprofloxacin on par with metronidazole for pouchitis

A propensity-matched study has found no significant difference in the effectiveness of ciprofloxacin, metronidazole, or combination therapy in the real-world setting for an initial episode of pouchitis after ileal pouch-anal anastomosis for ulcerative colitis.

Ciprofloxacin on par with metronidazole for pouchitis